Halozyme Therapeutics posts strong Q1 2025 earnings with 35% revenue growth, robust pipeline, and rising royalties.

Discover how the Virtus InfraCap U.S. Preferred Stock ETF leverages a unique strategy to generate income, hedge risks & ...

First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer's Disease Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts ...

2-Year U.S. Treasury Note Continuous Contract $103.344-0.203-0.20% 5-Year U.S. Treasury Note Continuous Contract $107.602-0.492-0.46% 10-Year U.S. Treasury Note Continuous Contract $110.203-0.609 ...

FTSE 100 Index 8,586.18 31.38 0.37% ...